Final analysis: phase II trial of Irinotecan/S-1/cetuximab (IRIS/Cet) as second line treatment in patients with KRAS exon2 wild type mCRC: HGCSG090...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter S. Yuki
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors S. Yuki1, Y. Komatsu2, H. Nakatsumi2, Y. Kawamoto2, T. Muranaka2, K. Sawada1, Y. Tsuji3, A. Hosokawa4, M. Nakamura5, O. Muto6, T. Sasaki7, I. Iwanaga8, K. Hatanaka9, A. Sato10, K. Eto11, K. Furukawa12, M. Tateyama13, Y. Takahashi14, S. Sogabe15, T. Honda16, N. Sakamoto1, Y. Sakata17
  • 1Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Sapporo, Japan, /
  • 2Department of Cancer Center, Hokkaido University Hospital, Sapporo, Japan, /
  • 3Department of Medical Oncology, Tonan Hospital, Sapporo, Japan, /
  • 4Department of Gastroenterology and Hematology, Faculty of Medicine, University of Toyama, Toyama, Japan, /
  • 5Department of Gastroenterology, Sapporo City General Hospital, Sapporo, Japan, /
  • 6Department of Medical Oncology, Japanese Red Cross Akita Hospital, Akita, Japan, /
  • 7Department of Internal Medicine, Hokkaido Gastroenterology Hospital, Sapporo, Japan, /
  • 8Department of Medical Oncology, Japanese Red Cross Kitami Hospital, Kitami, Japan, /
  • 9Department of Gastroenterology, Hakodate Municipal Hospital, Hakodate, Japan, /
  • 10Department of Medical Oncology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan, /
  • 11Department of Gastroenterology, Tomakomai City Hospital, Tomakomai, Japan, /
  • 12Department of Gastroenterology, Niigata City General Hospital, Niigata, Japan, /
  • 13Department of Internal Medicine, Tomakomai Nisshou Hospital, Tomakomai, Japan, /
  • 14Department of Gastroenterology, Hokkaido Cancer Center, Sapporo, Japan, /
  • 15Department of Medical Oncology, Kushiro Rosai Hospital, Kushiro, Japan, /
  • 16Department of Gastroenterology and Hepatology, Nagasaki University Hospital, Nagasaki, Japan, /
  • 17CEO, Misawa City Hospital, Misawa, Japan, /

Abstract

HGCSG0902 is the multicenter phase II study to investigate the safety and efficacy of irinotecan, S-1 (IRIS) plus cetuximab as second line treatment in patients with KRAS exon2 wild type mCRC. Response rate (RR) was 33.3% (95%CI 20.8-45.9%), therefore primary endpoint was met (Muto O, et al. ESMO 2014). Here we report an exploratory analysis of outcomes based on administration interval of cetuximab (every week [EW] vs bi-weekly [BW]).